Cyclosporine, Low-Density Lipoprotein, and Cholesterol

Mayo Clinic Proceedings

Volumn 63, Issue 10, 1988, Pages 1012-1021

  de GROEN, PIET C ^a  

^a Division of Gastroenterology and Internal Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYCLOSPORIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; STEROID MONOOXYGENASE;

DRUG DISTRIBUTION; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW;

EID: 0023745182     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-6196(12)64916-7     Document Type: Article

References (104)

1. The history of cyclosporin A and its significance
2. Effects of the new anti-lymphocytic peptide cyclosporin A in animals
3. Cyclosporin A in patients receiving renal allografts from cadaver donors
4. Cyclosporin A for the treatment of graft-versus-host disease in man
5. Liver transplantation with use of cyclosporin A and prednisone
6. Antischistosomal effects of cyclosporin A
7. Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process
8. Cyclophilin: a specific cytosolic binding protein for cyclosporin A
9. Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity
10. Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2
11. Inhibition of T-cell activity by cyclosporin A
12. HLA-DR antigens render interleukin-2-producer T lymphocytes sensitive to interleukin-1
13. Effect of cyclosporin A on T cell function in vitro: the mechanism of suppression of T cell proliferation depends on the nature of the T cell stimulus as well as the differentiation state of the responding T cell
14. Cyclosporin receptors on human lymphocytes
15. Binding of cyclosporine by human lymphocytes and phospholipid vesicles
16. Blood and tissue distribution of cyclosporine in humans and mice
17. The transport of cyclosporine in association with plasma lipoproteins in heart and liver transplant patients
18. Distribution and binding of cyclosporine in blood and tissues
19. Interaction of cyclosporin A with human lipoproteins
20. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood
21. A new method for measuring the free fraction of cyclosporin in plasma by equilibrium dialysis
22. Cyclosporin: measurement of fraction unbound in plasma
23. Tissue distribution, disposition, and metabolism of cyclosporine in rats
24. Cyclosporine levels in human tissues of patients treated for one week to one year
25. Low density lipoprotein receptors in bovine adrenal cortex. II. Low density lipoprotein binding to membranes prepared from fresh tissue
26. Cyclophilin: distribution and variant properties in normal and neoplastic tissues
27. Central nervous system toxicity after liver transplantation: the role of cyclosporine and cholesterol
28. Cyclosporine A-induced side effects related to a low total serum cholesterol level: an indication for a free cyclosporine A assay?
29. The free fraction of cyclosporine in plasma: clinical findings with a new method
30. High cyclosporin levels after bone marrow transplantation associated with hyper-triglyceridaemia (letter to the editor)
31. Distribution of cyclosporine in blood of a renaltransplant recipient with type V hyperlipoproteinemia
32. A receptor-mediated pathway for cholesterol homeostasis
33. Metabolism of cyclosporin A. II. Implication of the macrolide antibiotic inducible cytochrome P-450 3c from rabbit liver microsomes
34. Biochemical mechanisms underlying cyclosporine-induced nephrotoxicity: effect of concomitant administration of prednisolone
35. Long-term effects of cyclosporin A on cultured mouse pancreatic islets
36. Cyclosporin A inhibits rDNA transcription in lymphosarcoma P1798 cells
37. Effects of cyclosporin A (CsA) on LDL-receptor activity and bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat (abstract)
38. FK-506 enhances cyclosporine uptake by peripheral blood lymphocytes
39. Cyclosporin-A deposits in renal allografts
40. Uptake and metabolism of lactosylceramide on low density lipoproteins in cultured proximal tubular cells from normal and familial hypercholesterolemic homozygotes
41. Targeted killing of cultured cells by receptor-dependent photosensitization
42. Selective delivery of cytotoxic compounds to cells by the LDL pathway
43. Porphyrin-lipoprotein association as a factor in porphyrin localization
44. Effect of cyclosporine A on male reproduction in rats
45. Effect of cyclosporin A on the morphology and function of the ovary and fertility in the rabbit
46. Effect of cyclosporin on blood pressure and renin-aldosterone axis in rats
47. Cyclosporin A-induced hyperreninemic hypoaldosteronism: a model of adrenal resistance to angiotensin II
48. Direct augmentation by cyclosporin A of the vascular contractile response to nerve stimulation
49. Preparation and efficacy of cyclosporin-A liposomes for prolongation of cardiac allograft survival
50. Preliminary report: the use of liposome-encapsulated cyclosporine in a rat model
51. Efficacy of incorporating cyclosporine into liposomes to reduce its nephrotoxicity
52. Adverse effects of cyclosporine therapy following liver transplantation
53. Neurological complications following liver transplantation
54. Cyclosporine-associated central nervous system toxicity (letter to the editor)
55. Severe central-nervous-system toxicity associated with cyclosporin (letter to the editor)
56. Cerebral blindness and encephalopathy with cyclosporin A toxicity
57. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets
58. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system
59. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins
60. Nerve injury stimulates the secretion of apolipoprotein E by nonneuronal cells
61. mRNA for low density lipoprotein receptor in brain and spinal cord of immature and mature rabbits
62. Lipoproteins and their receptors in the central nervous system: characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain
63. Restrictive transport of a lipid-soluble peptide (cyclosporin) through the blood-brain barrier
64. Disturbance of blood-brain barrier after bone-marrow transplantation (letter to the editor)
65. Significance of middle molecules in the pathogenesis of hepatic encephalopathy
66. Experimental studies of blood brain barrier permeability in acute hepatic failure
67. Developing nervous tissue induces formation of blood-brain barrier characteristics in invading endothelial cells: a study using quail-chick transplantation chimeras
68. Astrocytes induce blood-brain barrier properties in endothelial cells
69. The astrocyte in liver disease
70. Effect of cyclosporine A on prostacyclin synthesis by vascular tissue
71. Cyclosporine inhibits prostacyclin production by cultured human endothelial cells
72. 2 release from vascular smooth muscle cells
73. Mechanism of bile acid biosynthesis in mammalian liver
74. Cerebrotendinous xanthomatosis: a review of biochemical findings of the patient population in the Netherlands
75. Familial diseases with storage of sterols other than cholesterol: cerebrotendinous xanthomatosis and sitosterolemia with xanthomatosis
76. Cerebrotendinous xanthomatosis: a defect in mitochondrial 26-hydroxylation required for normal biosynthesis of cholic acid
77. Psychiatric disorders in patients with cerebrotendinous xanthomatosis
78. Computed tomography in cerebrotendinous xanthomatosis
79. Magnetic resonance imaging in cerebrotendinous xanthomatosis
80. EEG in cerebrotendinous xanthomatosis (CTX)
81. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid
82. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis: effect of chenodeoxycholic acid
83. Critical issues in cyclosporine monitoring: report of the Task Force on Cyclosporine Monitoring
84. Expression of apolipoprotein E during nerve degeneration and regeneration
85. Role for apolipoproteins-E and A-I in nerve degeneration and regeneration (abstract)
86. Expression of apolipoprotein B, E(LDL) receptors and uptake of apolipoprotein E-containing lipoproteins by the regenerating rat sciatic nerve
87. Physicochemical properties of FK-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis
88. Effect of FK-506 on human mixed lymphocyte reaction in vitro
89. The influence of human plasma lipoproteins and fatty acids in immunological reactions
90. Suppressor macromolecules
91. Mitogenstimulated calcium ion accumulation by lymphocytes: influence of plasma lipoproteins
92. Regulatory serum lipoproteins: regulation of lymphocyte stimulation by a species of low density lipoprotein
93. Identification of a lymphocyte surface receptor for low density lipoprotein inhibitor, an immunoregulatory species of normal human serum low density lipoprotein
94. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In
95. Apoprotein E suppresses phytohemagglutinin-activated phospholipid turnover in peripheral blood mononuclear cells
96. Inhibition of T lymphocyte activation by cyclosporin A: interference with the early activation of plasma membrane phospholipid metabolism
97. The immunosuppressive activities of different cyclosporins are correlated to inhibition of the early membrane phospholipid metabolism in activated lymphocytes
98. Defective lipoprotein receptors and atherosclerosis: lessons from an animal counterpart of familial hypercholesterolemia
99. Overexpression of low density lipoprotein (LDL) receptor eliminates LDL from plasma in transgenic mice
100. Heart-liver transplantation in a patient with familial hypercholesterolaemia
101. Liver transplantation for treatment of cardiovascular disease: comparison with medication and plasma exchange in homozygous familial hypercholesterolemia
102. Combined transplantation of heart and liver from two different donors in a patient with familial type IIa hypercholesterolemia